Background: Systemic lupus erythematous (SLE) is a systemic autoimmune/inflammatory condition. Approximately 15-20% of patients develop symptoms before their 18th birthday and are diagnosed with juvenile-onset SLE (JSLE). Gender distribution, clinical presentation, disease courses and outcomes vary significantly between JSLE patients and individuals with adult-onset SLE. This study aimed to identify age-specific clinical and/or serological patterns in JSLE patients enrolled to the UK JSLE Cohort Study.

Methods: Patient records were accessed and grouped based on age at disease-onset: pre-pubertal (≤7 years), peri-pubertal (8-13 years) and adolescent (14-18 years). The presence of American College of Rheumatology (ACR) classification criteria, laboratory results, disease activity [British Isles Lupus Assessment Group (BILAG) and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2 K) scores] and damage [Systemic Lupus International Collaborating Clinics (SLICC) damage index] were evaluated at diagnosis and last follow up.

Results: A total of 418 JSLE patients were included in this study: 43 (10.3%) with pre-pubertal disease onset; 240 (57.4%) with peri-pubertal onset and 135 (32.3%) were diagnosed during adolescence. At diagnosis, adolescent JSLE patients presented with a higher number of ACR criteria when compared with pre-pubertal and peri-pubertal patients [pBILAG2004 scores: 9(4-20] vs. 7(3-13] vs. 7(3-14], respectively,  = 0.015] with increased activity in the following BILAG domains: mucocutaneous ( = 0.025), musculoskeletal ( = 0.029), renal ( = 0.027) and cardiorespiratory ( = 0.001). Furthermore, adolescent JSLE patients were more frequently ANA-positive ( = 0.034) and exhibited higher anti-dsDNA titres ( = 0.001). Pre-pubertal individuals less frequently presented with leukopenia ( = 0.002), thrombocytopenia ( = 0.004) or low complement ( = 0.002) when compared with other age groups. No differences were identified in disease activity (pBILAG2004 score), damage (SLICC damage index) and the number of ACR criteria fulfilled at last follow up.

Conclusions: Disease presentations and laboratory findings vary significantly between age groups within a national cohort of JSLE patients. Patients diagnosed during adolescence exhibit greater disease activity and "classic" autoantibody, immune cell and complement patterns when compared with younger patients. This supports the hypothesis that pathomechanisms may vary between patient age groups.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528537PMC
http://dx.doi.org/10.1177/0961203320909156DOI Listing

Publication Analysis

Top Keywords

jsle patients
24
age groups
16
disease activity
16
systemic lupus
12
patients
10
lupus erythematosus
8
jsle
8
slicc damage
8
diagnosed adolescence
8
adolescent jsle
8

Similar Publications

Systemic lupus erythematosus (SLE) is an autoimmune disorder that can affect various organs. Juvenile-onset SLE (jSLE) may be more severe than the adult-onset form, but the diagnosis and classification remain challenging due to the complex nature of the condition and its resemblance to other conditions. Antinuclear antibodies (ANA) are the immunological hallmark of SLE, but their limited specificity poses challenges.

View Article and Find Full Text PDF
Article Synopsis
  • This study focused on serum IFN-α2 as a potential marker for disease activity and flare prediction in juvenile systemic lupus erythematosus (jSLE).
  • Researchers analyzed 222 serum samples from jSLE patients, healthy controls, and juvenile idiopathic arthritis patients to compare IFN-α2 levels across groups and assess its predictive value for disease flares.
  • The results indicated that higher IFN-α2 levels were associated with active disease states and could predict flare risk in jSLE patients, suggesting its utility for monitoring and managing the condition.
View Article and Find Full Text PDF

Systemic lupus erythematosus (SLE) is an autoimmune disease involving multiple organ systems that often mimic other conditions. The majority of patients with SLE show mucocutaneous manifestations, fatigue, fever, rheumatological manifestations, and weight loss as initial symptoms. SLE is classically managed medically with hydroxychloroquine, glucocorticoids, and/or immunosuppressives.

View Article and Find Full Text PDF

Contributors to Organ Damage in Childhood Lupus: Corticosteroid Use and Disease Activity.

Rheumatology (Oxford)

October 2024

Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.

Background: Awareness of paediatric-specific predictors of damage in Childhood-lupus is needed to inform mitigation measures.

Objectives: To ascertain how clinical and demographic variables correlate with damage accrual and identify predictors of damage.

Methods: Analysis included UK JSLE Cohort Study participants.

View Article and Find Full Text PDF
Article Synopsis
  • The study analyzes clinical features in juvenile systemic lupus erythematosus (J-SLE) to better classify its patient subgroups through cluster analysis.
  • A total of 404 patients were examined, leading to the identification of four distinct clinical phenotypes, each exhibiting different symptoms and disease severities.
  • The findings suggest a need for tailored therapies, highlighting the importance of including low-dose aspirin in treatment plans, while further research is necessary to confirm these phenotype patterns.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!